title: An update on anti-TNF agents in ulcerative colitis.
abstract: Anti-tumor necrosis factor-α agents are key therapeutic options for the treatment of ulcerative colitis. Their efficacy and safety have been shown in large randomized controlled trials. The key evidence gained from these trials of infliximab, adalimumab, and golimumab is reviewed along with their effect on mucosal healing and long-term outcomes. Also reviewed are methods for optimizing their effectiveness, including therapeutic drug monitoring and treat-to-target strategies. Finally, remaining unresolved questions regarding their role and effectiveness are considered including how these may be addressed in future clinical trials.
authors.affiliation: Department of Gastroenterology, Academic Medical Centre, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Samaan
authors.affiliation: Division of Gastroenterology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0956, 92103, USA.
authors.forename: Preet
authors.initials: P
authors.lastname: Bagi
authors.affiliation: Division of Gastroenterology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0956, 92103, USA.
authors.forename: Niels
authors.initials: N
authors.lastname: Vande Casteele
authors.affiliation: Department of Gastroenterology, Academic Medical Centre, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands.
authors.forename: Geert R
authors.initials: GR
authors.lastname: D'Haens
authors.affiliation: Division of Gastroenterology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0956, 92103, USA. Electronic address: bglevesque@ucsd.edu.
authors.forename: Barrett G
authors.initials: BG
authors.lastname: Levesque
mesh_terms: D000068879:Adalimumab; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D006801:Humans; D000069285:Infliximab; D007413:Intestinal Mucosa / Q000187:drug effects; D060046:Maintenance Chemotherapy; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014945:Wound Healing / Q000187:drug effects
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; C529000:golimumab; D000069285:Infliximab; D000068879:Adalimumab
keywords: Adalimumab; Anti-TNF; Golimumab; Infliximab; UC; Ulcerative colitis